RP-HPLC Method for Development, Validation and Assay of Desidustat in Pharmaceutical Formulation

Q: How many days will it take for my paper to be published?

The review time for papers is not fixed. However, if the paper is accepted and the author completes the processing charges formalities, the paper will be published within a few working days.

Q: I would like to receive a hard copy of the journal materials. Are there any additional charges?

You can log in to the author portal and pay 500 INR to receive the hard copy materials.

Ameya lanjewar; Dr. Dindayal Patidar

RP-HPLC Method for Development, Validation and Assay of Desidustat in Pharmaceutical Formulation

Authors: Ameya lanjewar, Dr. Dindayal Patidar

Unique Paper ID: 167480
Volume: 11
Issue: 3
PageNo: 1685-1698

Keywords: Desidustat Eclipse XDB C18 (150x4.6 Mm 5µ) RP-HPLC Development And Validation

Abstract:
Desidustat is an orally bioavailable, hypoxia- inducible factor prolyl hydroxylase inhibitor and used to treat anemia of chronic kidney disease. An accurate, precise and robust reverse phase HPLC methods was developed and validated as per ICH guideline. An analytical column eclipse XDB C18 (150x4.6 mm,5µ) was used at flow rate 1.0 ml/min in the mobile phase ratio of 0.1% orthophosphoric acid and methanol 38:72 at 235 nm wavelength. These approach can be effectively utilized for the development and validation of desidustat in pharmaceutical formulation.

Download article

email to a friend

Cite This Article

ISSN: 2349-6002
Volume: 11
Issue: 3
PageNo: 1685-1698

RP-HPLC Method for Development, Validation and Assay of Desidustat in Pharmaceutical Formulation

Available:https://ijirt.org/article?manuscript=167480

Impact Factor
8.01 (Year 2024)

UGC Approved
Journal no 47859

Join Our IPN

IJIRT Partner Network

Submit your research paper and those of your network (friends, colleagues, or peers) through your IPN account, and receive 800 INR for each paper that gets published.

Join Now